We previously have demonstrated that targeting ABCB1 by CRISPR/Cas9-based genome editing reverses ABCB1-mediated multidrug resistance in cancer cells, resulting in the increase of the sensitivity and intracellular accumulation of the anti-cancer drugs (36). The gene discussed is ABCB1; the disease is cancer.